Katarzyna W. L.
- Country
- Poland
- Department
- NA
Research Overview
- A 40-Week Randomized Study Evaluating the Efficacy and Safety of Weekly Insulin Icodec/Semaglutide Versus Daily Insulin Glargine in Type 2 Diabetes Patients
- Efficacy and Safety of Gliclazide MR and Dapagliflozin, with or without Metformin, in Type 2 Diabetes Patients Inadequately Controlled on Dapagliflozin
- Efficacy and Safety Evaluation of Pioglitazone with Metformin and Empagliflozin in Type 2 Diabetes Mellitus Patients with Inadequate Glycemic Control
Data & Insights
Has run more than one trial at 203 of 857 partner sites.
Specializations
Metabolic Disorders
This investigator specializes in treating non-alcoholic steatohepatitis (NASH) and its relation to liver health, with particular focus on innovative therapeutic approaches for improving liver histology and reducing fibrosis.
- NASH treatment development
- Liver fibrosis management
- Combination therapy approaches
Diabetes Management
The investigator focuses on advancing treatments for Type 2 diabetes, exploring various therapeutic combinations including novel weekly insulin formulations and oral antidiabetic medications.
- Glycemic control optimization
- Innovative insulin therapies
- Combined treatment strategies
Preventive Medicine
Research interests extend to preventive healthcare, particularly in infectious disease prevention and vaccine development for older adults, including studies on influenza and respiratory syncytial virus vaccines.
- Vaccine immunogenicity
- Elderly population health
- Co-administration studies
Cardiovascular Health
The investigator studies cardiovascular outcomes in metabolic conditions, with particular attention to obesity-related cardiovascular safety and therapeutic interventions.
- Cardiovascular risk assessment
- Weight management therapies
- Safety monitoring protocols
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.